Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 117Carcinoma, Transitional Cell 39Testicular Neoplasms 23Urethral Neoplasms 18Testicular Germ Cell Tumor 14Ovarian Neoplasms 13Teratoma 12Prostatic Neoplasms 11Endodermal Sinus Tumor 11Seminoma 10Neoplasms 10Carcinoma, Embryonal 9Ureteral Neoplasms 8Melanoma 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Renal Cell 7Stomach Neoplasms 6Penile Neoplasms 6Neoplasm Metastasis 6Colorectal Neoplasms 6Breast Neoplasms 6Urologic Neoplasms 5Sarcoma 5Pancreatic Neoplasms 5Urothelial Cancer 4Lung Neoplasms 4Central Nervous System Neoplasms 4Wilms Tumor 3Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3

Interventions

Docetaxel 4radium Ra 223 dichloride 2Prednisone 2sargramostim 1gossypol acetic acid 1epothilone B 1cabazitaxel 1bafetinib 1Sunitinib 1PE regimen 1Mycobacterium w vaccine 1Interleukin-2 1Injections 1Everolimus 1Etoposide 1Denosumab 1Cyclophosphamide 1Cisplatin 1Carboplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone Refractory Prostate Cancer × Cisplatin × Genitourinary × Clear all
NCT02208583 2014-08-05

Molecular Phenotype Changes and Personalized Treatment for CRPC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
150 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡